Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease

INTRODUCTION: In patients with moderate to severe Crohn’s disease (CD), intravenous induction and subcutaneous maintenance dosing with risankizumab was efficacious and well tolerated. Long-term management of CD via self-administration of risankizumab using an on-body injector (OBI) may improve treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Loftus, Edward V., Griffith, Jenny, Neimark, Ezequiel, Song, Alexandra, Wallace, Kori, Nannapaneni, Sujani, Zhou, Ji, Byrne, Rachel, Kligys, Kristina, Pang, Yinuo, Liao, Xiaomei, Kalabic, Jasmina, Dubinsky, Marla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011765/
https://www.ncbi.nlm.nih.gov/pubmed/36917429
http://dx.doi.org/10.1007/s12325-023-02477-2

Ejemplares similares

Ejemplares similares